PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1677450-3	1991	In the present in vitro study, the formation in human T cells (MOLT-4, ATH8, and CCRF-CEM) of the pharmacologically active metabolite of ddIno and ddAdo, 2",3"-dideoxyadenosine-5"-triphosphate (ddATP), was found to be stimulated 2-4-fold by appropriate concentrations of inosinate dehydrogenase (IMPD) inhibitors such as ribavirin, tiazofurin, and mycophenolic acid.	Didanosine	137-142	inosine monophosphate dehydrogenase 1	Homo sapiens	296-300	
1677450-5	1991	No change was noted in the intracellular concentration of the corresponding physiological deoxynucleoside-5"-triphosphate, dATP; positive correlation was observed, however, between the increase in ddATP formation from ddIno and the increase in intracellular IMP occurring as a consequence of IMPD inhibition.	Didanosine	218-223	inosine monophosphate dehydrogenase 1	Homo sapiens	292-296	
1677450-6	1991	The results support the hypothesis that the stimulation of ddATP formation seen when ddIno is combined with ribavirin or other IMPD inhibitors is a consequence of an increased concentration of IMP, the major phosphate donor for the initial phosphorylation step in the anabolism of ddIno to ddATP, i.e., ddIno----ddIMP.	Didanosine	281-286	inosine monophosphate dehydrogenase 1	Homo sapiens	127-131